IMGN News and Press, ImmunoGen Inc. From 02/15/22

ImmunoGen (NASDAQ:IMGN) shares have added ~3% in the pre-market on Tuesday after the company announced a licensing deal with Eli Lilly (NYSE:LLY) to research, develop, and commercialize antibody-drug conjugates based on its camptothecin platform. ADCs covered by the deal will be dir...

ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results. Management ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upc...

ImmunoGen (NASDAQ:IMGN) granted non-qualified stock option awards to four new employees to buy a total of 525.6K common shares under the inducement equity incentive plan. The options have an exercise price of $5.65/share. For further details see: ImmunoGen reports inducement g...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga, MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs. “As evidence generation a...

ImmunoGen Inc. (NASDAQ: IMGN) , an oncology biotech company that specializes in the use of antibody-drug conjugates (ADCs) to make chemotherapy treatments more effective, saw its shares rise by 20.3% in December, according to data provided by S&P Global Market Intelligence ....

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation i...

ImmunoGen is a turnaround stock that weathered the 2021 Biotech Bear market quite well. The lead medicine, mirvetuximab, recently demonstrated the robust data for the Phase 3 SORAYA trial. The company is expected to file a BLA for mirvetuximab as a treatment for resistant ovarian ...

Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation S...